Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapeutic vaccination for cancer.

Literature DB >> 10729237

Therapeutic vaccination for cancer.

D M Pardoll¹.

Abstract

Entities: Disease

Mesh：

Substances：
Cancer Vaccines

Year: 2000 PMID： 10729237 DOI： 10.1006/clim.1999.4819

Source DB: PubMed Journal: Clin Immunol ISSN： 1521-6616 Impact factor: 3.969

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

1. Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma.

Authors: Huafeng Wei; Pu Liu; Elizabeth Swisher; Yuen Yee Yip; Jee Hang Tse; Kathy Agnew; Karl Erik Hellström; Ingegerd Hellström
Journal: J Immunother Date: 2012-04 Impact factor: 4.456

2. Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma.

Authors: David A Rodeberg; Rebecca A Nuss; Carrie J Heppelmann; Esteban Celis
Journal: Cancer Immunol Immunother Date: 2004-11-20 Impact factor: 6.968

3. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes.

Authors: David A Rodeberg; Rebecca A Nuss; Sherine F Elsawa; Esteban Celis
Journal: Clin Cancer Res Date: 2005-06-15 Impact factor: 12.531

Review 4. Therapeutic vaccination with tumor cells that engage CD137.

Authors: Karl Erik Hellstrom; Ingegerd Hellstrom
Journal: J Mol Med (Berl) Date: 2003-02-08 Impact factor: 4.599

5. Immunotherapy of tumors with recombinant adenovirus encoding macrophage inflammatory protein 3beta induces tumor-specific immune response in immunocompetent tumor-bearing mice.

Authors: Jian-mei Hou; Xia Zhao; Ling Tian; Gang Li; Ru Zhang; Bing Yao; Hong-xin Deng; Jin-liang Yang; Yu-quan Wei
Journal: Acta Pharmacol Sin Date: 2009-03 Impact factor: 6.150

Therapeutic vaccination for cancer.

1. Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma.

2. Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma.

3. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes.

Review 4. Therapeutic vaccination with tumor cells that engage CD137.

5. Immunotherapy of tumors with recombinant adenovirus encoding macrophage inflammatory protein 3beta induces tumor-specific immune response in immunocompetent tumor-bearing mice.

Review 6. Biological response modifiers in cancer.

Review 7. Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers.

8. Low-dose interferon-gamma-producing human neuroblastoma cells show reduced proliferation and delayed tumorigenicity.